Covidien (COV) Tops Q4 EPS by 3c, Reaffirms Guidance
Tweet
Share
E-mailGet Alerts COV Hot Sheet
Join SI Premium – FREE
Covidien (NYSE: COV) reported Q4 adjusted EPS of $1.08, $0.03 better than the analyst estimate of $1.05. Revenue for the quarter came in at $3.08 billion versus the consensus estimate of $3.03 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
- Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
